GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Cash Flow from Financing

Merus NV (Merus NV) Cash Flow from Financing : $260.03 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Merus NV received $22.61 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $7.54 Mil on other financial activities. In all, Merus NV earned $30.16 Mil on financial activities for the three months ended in Mar. 2024.


Merus NV Cash Flow from Financing Historical Data

The historical data trend for Merus NV's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Cash Flow from Financing Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.23 39.52 281.96 58.74 230.09

Merus NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 65.97 162.40 1.50 30.16

Merus NV Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Merus NV's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Merus NV's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $260.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merus NV  (NAS:MRUS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Merus NV's issuance of stock for the three months ended in Mar. 2024 was $22.61 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Merus NV's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Merus NV's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Merus NV received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Merus NV's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Merus NV paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Merus NV's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Merus NV received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Merus NV's other financing for the three months ended in Mar. 2024 was $7.54 Mil. Merus NV received $7.54 Mil on other financial activities.


Merus NV Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Merus NV's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Industry
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM